Qiagen NV
QGEN48.560USD
+1.340+2.84%
Fechamento 11/25, 16:00（ET）Cotações atrasadas em 15 min
10.53BValor de mercado
25.98P/L TTM
Mais detalhes de Qiagen NV Empresa
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Informações de Qiagen NV
Código da empresaQGEN
Nome da EmpresaQiagen NV
Data de listagemSep 01, 1996
CEOMr. Thierry Bernard
Número de funcionários5765
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 01
EndereçoHulsterweg 82
CidadeVENLO
Bolsa de valoresNYSE Consolidated
PaísNetherlands
Código postal5912 PL
Telefone31773556600
Sitehttps://www.qiagen.com/
Código da empresaQGEN
Data de listagemSep 01, 1996
CEOMr. Thierry Bernard
Executivos da empresa Qiagen NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por EmpresaUSD
Nome
Receita
Proporção
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
Por RegiãoUSD
Nome
Receita
Proporção
United States
260.49M
48.82%
Europe & Middle East & Africa
179.30M
33.61%
Asia, Pacific & Rest of the World
73.46M
13.77%
Other Americas
20.29M
3.80%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Outro
68.78%
Investidores
Investidores
Proporção
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Outro
68.78%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
48.71%
Investment Advisor
25.43%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.05%
Outro
14.86%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wellington Management Company, LLP
26.02M
12%
+1.59M
+6.49%
Jun 30, 2025
MFS Investment Management
23.48M
10.83%
-787.04K
-3.24%
Jun 30, 2025
The Vanguard Group, Inc.
9.16M
4.22%
+372.54K
+4.24%
Jun 30, 2025
T. Rowe Price International Ltd
5.94M
2.74%
+1.79M
+43.10%
Jun 30, 2025
DWS Investment GmbH
3.30M
1.52%
+2.74M
+482.72%
Jun 30, 2025
EARNEST Partners, LLC
4.20M
1.94%
+395.58K
+10.39%
Jun 30, 2025
Amundi Asset Management, SAS
3.98M
1.83%
-217.72K
-5.19%
Jun 30, 2025
Boston Partners
2.36M
1.09%
+13.48K
+0.58%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
9.47%
+174.28K
+0.86%
Sep 10, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
First Trust Nasdaq Lux Digi Health Solutions ETF
3.85%
Global X Genomics & Biotechnology ETF
3.76%
Invesco Biotechnology & Genome ETF
2.45%
VanEck Biotech ETF
1.81%
ROBO Global Healthcare Technology & Innovation ETF
1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.18%
Franklin Genomic Advancements ETF
1%
iShares Health Innovation Active ETF
0.93%
Burney US Factor Rotation ETF
0.75%
WisdomTree International Multifactor Fund
0.68%
Ver Mais
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção3.85%
Global X Genomics & Biotechnology ETF
Proporção3.76%
Invesco Biotechnology & Genome ETF
Proporção2.45%
VanEck Biotech ETF
Proporção1.81%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proporção1.18%
Franklin Genomic Advancements ETF
Proporção1%
iShares Health Innovation Active ETF
Proporção0.93%
Burney US Factor Rotation ETF
Proporção0.75%
WisdomTree International Multifactor Fund
Proporção0.68%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Data
Tipo
Proporção
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Perguntas frequentes
Quem são os cinco principais acionistas de Qiagen NV?
Os cinco principais acionistas de Qiagen NV são:
Wellington Management Company, LLP detém 26.02M Ações, representando 12.00% do total de Ações.
MFS Investment Management detém 23.48M Ações, representando 10.83% do total de Ações.
The Vanguard Group, Inc. detém 9.16M Ações, representando 4.22% do total de Ações.
T. Rowe Price International Ltd detém 5.94M Ações, representando 2.74% do total de Ações.
DWS Investment GmbH detém 3.30M Ações, representando 1.52% do total de Ações.
Wellington Management Company, LLP detém 26.02M Ações, representando 12.00% do total de Ações.
MFS Investment Management detém 23.48M Ações, representando 10.83% do total de Ações.
The Vanguard Group, Inc. detém 9.16M Ações, representando 4.22% do total de Ações.
T. Rowe Price International Ltd detém 5.94M Ações, representando 2.74% do total de Ações.
DWS Investment GmbH detém 3.30M Ações, representando 1.52% do total de Ações.
Quais são os três principais tipos de acionistas de Qiagen NV?
Os três principais tipos de acionistas da Qiagen NV são:
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Quantas instituições possuem ações da Qiagen NV (QGEN)?
Em 2025Q3, 996 instituições possuíam ações da Qiagen NV, com valor de mercado aproximado de 177.81M, representando 82.00% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em -5.53%.
Qual é a maior fonte de receita da Qiagen NV?
Em FY2025Q2, o segmento de negócios Consumables and Related Revenues gerou a maior receita para Qiagen NV, totalizando 476.33M e representando 89.28% da receita total.
